Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2006-06-15
2010-12-07
Landsman, Robert (Department: 1646)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S185100, C514S012200, C530S350000, C530S399000
Reexamination Certificate
active
07846453
ABSTRACT:
The invention concerns a novel neuregulin related ligand (NRG3) including fragments and variants thereof, as new members of the neuregulin family of compounds. The invention also concerns methods and means for producing NRG3. The native polypeptides of the invention are characterized by containing an extracellular domain including an EGF-like domain, a transmembrane domain and a cytoplasmic domain. Isolated nucleotide sequences encoding such polypeptides, expression vectors containing the nucleotide sequences, recombinant host cells transformed with the vectors, and methods for the recombinant production for the novel NRG3s are also within the scope of the invention.
REFERENCES:
patent: 4892538 (1990-01-01), Aebischer et al.
patent: 5011472 (1991-04-01), Aebischer et al.
patent: 5714147 (1998-02-01), Capon et al.
patent: 5770567 (1998-06-01), Ho et al.
patent: 6121415 (2000-09-01), Godowski et al.
patent: 6727077 (2004-04-01), Young et al.
patent: 2004/0048295 (2004-03-01), Young et al.
patent: WO 92/19195 (1992-11-01), None
patent: WO 93/25673 (1993-12-01), None
patent: WO 95/05452 (1995-02-01), None
patent: WO 96/15244 (1996-05-01), None
patent: WO 96/36720 (1996-11-01), None
patent: WO 97/09425 (1997-03-01), None
patent: WO 98/57989 (1998-12-01), None
Hirsch E. Neuroinflammation in Parkinson's disease: a target for neuroprotection. Lancet Neurol. 2009, vol. 8, p. 392-397.
Walker, F.O. Huntington's disease. Lancet. 2007, vol. 369, p. 218-228.
Jackowski A. Neural injury repair: hope for the future as barriers to effective CNS regeneration become clearer. Br. J. Neurosurgery. 1995, vol. 9, p. 303-317.
Vickers J.C. A vaccine against Alzheimer's disease. Drugs Aging. 2002, vol. 19(7), p. 487-494.
Penderis J. et al. Increasing local levels of neuregulin (glial growth factor-2) by direct infusion into areas of demyelination does not alter remyelination in the rat CNS. Eur. J. Neuroscience. 2003, vol. 18, p. 2253-2264.
Carteron C, et al. Characterization of a neural-specific splicing form of the human neuregulin 3 gene involved in oligodendrocyte survival. J. Cell Science. 2006. vol. 119, p. 898-909.
Aebischer et al., “Intrathecal delivery of CNTF using encapsulated genetically modified xenogenic cells in amyotrophic lateral sclerosis patinents”Nature Medicine(published erratum appears in Nat Med Sep. 1996; 2(9) :1041) 2(6) :696-699 (Jun. 1996).
Barbacci et al., “The structural basis for the specificity of epidermal growth factor and heregulin binding”Journal of Biological Chemistry(published erratum appears in J Biol Chem Nov. 24, 1995;270(47) :28494) 270(16) :9585-9589 (Apr. 21, 1995).
Beerli et al., “Epidermal growth factor-related peptides activate distinct subsets of ErbB receptors and differ in their biological activities”Journal of Biological Chemistry271 (11) :6071-6076 (Mar. 15, 1996).
Blobel, G., “Intracellular protein topogenesis”Proc. Natl. Acad. Sci. USA77(3) :1496-1500 (Mar. 1980).
Bork, P., “Powers and Pitfalls in Sequence Analysis: The 70% Hurdle”Genome Research10(4) :398-400 (Apr. 2000).
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions”Science247:1306-1310 (1990).
Burgess et al., “Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin-binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue”Journal of Cell Biology111:2129-2138 (Nov. 1990).
Carraway and Cantley, “A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling”Cell78:5-8 (Jul. 15, 1994).
Carraway et al., “Neuregulin-2, A New Ligand of ErbB3/ErbB4-Receptor Tyrosine Kinases”Nature387:512-516 (May 1997).
Carraway et al., “The erbB3 gene product is a receptor for heregulin”Journal of Biological Chemistry269(19):14303-14306 (1994).
Chang et al., “Ligands for ErbB-Family Receptors Encoded by a Neuregulin-Like Gene”Nature387:509-512 (May 29, 1997).
Culouscou et al., “HER4 Receptor Activation and Phosphorylation of Shc Proteins by Recombinant Heregulin-Fc Fusion Proteins”Journal of Biological Chemistry270(21) :12857-12863 (May 26, 1995).
Derynck et al., “Human transforming growth factor-α: Precursor structure and expression inE. coli”Cell38:287-297 (1984).
Falls et al., “Aria, a protein that stimulates acetylcholine receptor synthesis, is a member of the Neu ligand family”Cell72:801-815 (1993).
Godowski et al., “Characterization of the human growth hormone receptor gene and demonstration of a partial gene deletion in two patients with Laron-type dwarfism”Proc. Natl. Acad. Sci. USA86:8083-8087 (1989).
Higashiyama et al., “A Heparin-Binding Growth Factor Secreted by Macrophage-Like Cells That is Related to EGF”Science251:936-939 (1991).
Hijazi et al., “NRG-3 in human breast cancers: Activation of multiple erbB family proteins” .Int. J. Oncol. 13(5):1061-1067 (Nov. 1998).
Hillier et al. (Genbank Database Accession No. H49100) (1995).
Ho, W., et al., “Sensory and Motor Neuron-derived Factor”Journal of Biological Chemistry270(24) :14523-14532 (Jun. 16, 1995).
Holmes et al., “Identification of Heregulin, A Specific Activator of p185erbB2”Science256:1205-1210 (May 22, 1992).
Karunagaran et al., “ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer”EMBO Journal15(2) :254-264 (1996).
Kita et al., “NDF/heregulin stimulates the phosphorylation of Her3/erbB3”FEBS letters349(1):139-143 (Jul. 25, 1994).
Lazar et al., “Transforming Growth Factor α: Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities”Molecular&Cellular Biology8 (3) :1247-1252 (Mar. 1988).
Nagai et al., “Molecular cloning of cDNA coding for human preprourokinase”Gene36(1-2) :183-188 (1985).
Plowman et al., “Heregulin Induces Tyrosine Phosphorylation of HER4/p180erbB4”Nature(Letters to Nature) 366:473-475 (Dec. 2, 1993).
Plowman et al., “The Amphiregulin Gene Encodes a Novel Epidermal Growth Factor-Related Protein with Tumor-Inhibitory Activity”Molecular&Cellular Biology10:1969-1981 (1990).
Riese et al., “The cellular response to neuregulins is governed by complex interactions of the erbB receptor family”Molecular&Cellular Biology(published erratum appears in Mol Cell Biol Feb. 1996; 16(2) :735) 15(10) :5770-5776 (Oct. 1995).
Sabatini et al., “Mechanisms for the incorporation of proteins in membranes and organelles”Journal of Cell Biology92(1) :1-22 (Jan. 1982).
Sasada et al., “Cloning and expression of cDNA encoding human betacellulin, a new member of the EGF family”Biochemical&Biophysical Research Communications190(3) :1173-1179 (Feb. 15, 1993).
Sliwkowski et al., “Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin”Journal of Biological Chemistry269(20) :14661-14665 (May 20, 1994).
Toyoda et al., “Molecular cloning of mouse epiregulin, a novel epidermal growth factor-related protein, expressed in the early stage of development”FEBS Letters377(3) :403-407 (Dec. 27, 1995).
Tzahar et al., “ErbB-3 and ErbB-4 Function as the Respective Low and High Affinity Receptors of All Neu Differentiation Factor/Heregulin Isoforms”Journal of Biological Chemistry269(40) :25226-25233 (1994).
Wickner et al., “Multiple mechanisms of protein insertion into and across membranes”Science230(4724):400-407 (Oct. 25, 1985).
Zhang et al., “Neuregulin-3 (NRG3): A novel neural tissue-enriched protein that binds and activates ErbB4”Proc. Natl. Acad. Sci. USA94:9562-9567 (Sep. 22, 1997).
Culouscou et al., “HER4 Receptor Activation and Phosphorylation of Shc Proteins by Recombinant Heregulin-Fc
Godowski Paul J.
Mark Melanie Rose
Zhang Dong Xiao
Arnold & Porter LLP
Dreger Ginger R.
Genentech Inc.
Hissong Bruce D
Landsman Robert
LandOfFree
Methods of stimulating ErbB4 receptor phosphorylation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of stimulating ErbB4 receptor phosphorylation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of stimulating ErbB4 receptor phosphorylation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4160445